Baxter International Inc
NYSE:BAX
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Baxter International Inc
NYSE:BAX
|
10.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.8B AUD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
137.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.1B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Baxter International Inc
Glance View
Baxter International Inc. finds its roots in the early 1930s, a time when the healthcare landscape was vastly different. Founded by Donald Baxter, a medical doctor seeking to improve the quality and safety of intravenous therapy, the company initially focused on researching and developing safe ways to provide patients with sterile intravenous solutions. As the years unfolded, Baxter transformed itself from a small operation into a globally recognized healthcare giant. Today, it operates in the realm of lifesaving medical products and services, specializing in the development of essential pharmaceuticals, clinical nutrition for hospitals, advanced kidney care solutions, and critical care technology that healthcare providers depend on daily. Central to Baxter's business model is its commitment to innovation and improving patient outcomes, which drives its success and profitability. By leveraging its expertise in areas like renal and hospital products, Baxter is able to cultivate a diversified portfolio. This diversification not only helps the company mitigate risks but also strengthens its market position. Revenue streams are generated through the manufacture and sale of medical devices and pharmaceuticals, catering mostly to hospitals, clinics, and renal care centers worldwide. Baxter consistently reinvests in its research and development, aiming to pioneer novel therapies and products that address the evolving needs of the healthcare sector, ensuring that it remains a key player in the ongoing story of medical progress.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Baxter International Inc is 6.4%, which is below its 3-year median of 7.3%.
Over the last 3 years, Baxter International Inc’s Operating Margin has decreased from 6.4% to 6.4%. During this period, it reached a low of 3.2% on Sep 30, 2024 and a high of 10.1% on Dec 31, 2023.